New insider activity at Precigen ( (PGEN) ) has taken place on October 1, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Jeffrey Kindler has recently made a significant move by selling 174,360 shares of Precigen stock, amounting to a total value of $604,191. This transaction highlights a notable shift in the holdings of a key figure within the company.
Recent Updates on PGEN stock
Recent developments for Precigen (PGEN) include the conversion of 79,000 shares of its Series A Convertible Perpetual Preferred Stock into 54,937,411 shares of common stock, executed under the company’s Amended and Restated Articles of Incorporation. Additionally, Precigen secured a 5-year senior secured term loan facility of up to $125 million with Pharmakon Advisors, LP, to support the commercialization of its novel immunotherapy, PAPZIMEOS. These strategic moves, along with product approvals, provide growth potential but are offset by financial instability and valuation concerns. Analysts maintain a Hold rating with a $3.00 price target, reflecting a balance between strong technical momentum and corporate events against weak financial performance.
Spark’s Take on PGEN Stock
According to Spark, TipRanks’ AI Analyst, PGEN is a Neutral.
Precigen’s overall stock score reflects a mix of strong technical momentum and positive corporate events, offset by weak financial performance and valuation concerns. The company’s recent strategic moves and product approvals provide growth potential, but financial instability remains a significant risk.
To see Spark’s full report on PGEN stock, click here.
More about Precigen
YTD Price Performance: 204.63%
Average Trading Volume: 8,755,671
Technical Sentiment Signal: Buy
Current Market Cap: $1.08B